Drug Topics
MAY 20, 2024
Health care providers must listen to patients who voice their experiences with post–COVID-19 condition symptoms. Only then can a clearer picture of the condition emerge for the millions of patients who have the near-invisible disease.
Pharmacy Times
MAY 20, 2024
New research study reveals the potential of community pharmacists for minor ailment treatment, allowing for diversified patient care during growing health care shortage.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MAY 20, 2024
WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to testify before the House Committee on Oversight and Accountability next month, four sources familiar with the planning told STAT. Executives from Optum, CVS Caremark, and Express Scripts, owned by Cigna, were asked to testify before the panel on June 4.
Pharmacy Times
MAY 20, 2024
Aflibercept-jbvf (Yesafili; Biocon Biologics) and aflibercept-yszy (Opuviz; Biogen) are the first interchangeable biosimilars to aflibercept (Eylea; Regeneron).
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
MAY 20, 2024
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an increasingly urgent threat: An unending stream of overheated marketing. To read of AI’s feats in press releases is to learn of a miracle product on the verge of unraveling biology’s most enduring secrets. It can map molecules and accurately predict how they fit together on computer screens.
Pharmacy Times
MAY 20, 2024
Despite the finding, the authors suggest further research is done to better understand the mechanisms behind the interactions between asthma, sleep, and depression.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Drug Topics
MAY 20, 2024
A poster presented at Digestive Disease Week showed that patients with MASLD taking semaglutide achieved significant weight loss while preserving skeletal muscle indices.
Fierce Healthcare
MAY 20, 2024
Six months after launching its weight loss program, online health and wellness company Hims & Hers added compounded GLP-1 medications to its offerings. | Six months after launching its weight loss program, online health and wellness company Hims & Hers added compounded GLP-1 medications to its offerings.
STAT
MAY 20, 2024
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him. For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’
Fierce Healthcare
MAY 20, 2024
The Department of Health and Human Services’ (HHS’) research funding agency is floating more than $50 million to developers who can build a scalable cybersecurity platform able to keep hospitals' c | The UPGRADE program will be handing out millions to those with the best pitches on how to detect hospital cybersecurity weaknesses and deploy fixes with minimal interruptions to care delivery.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
MAY 20, 2024
Belimumab (Benlysta; GSK) is a B-lymphocyte stimulator-specific inhibiting monoclonal antibody.
STAT
MAY 20, 2024
WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by a shakeup, according to five sources familiar with the planning. A few senior leaders are expected to depart as part of the reorganization.
pharmaphorum
MAY 20, 2024
Unlocking biotech insights: discover the latest advancements in biotech with our top picks for podcasts. Stay informed and up-to-date with industry trends and news by listening to some of the best biotech podcasts featuring expert analysis, discussions of ethical issues, and interviews with industry leaders.
Pharmaceutical Technology
MAY 20, 2024
Nearly 30,000 people, including children in clinical trials, were infected with hepatitis C and HIV from contaminated blood products in the 1970s and 1980s.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
MAY 20, 2024
In 2014, the cobas human papillomavirus test was approved by the FDA for first-line, primary screening in women aged 25 years and older.
Drug Topics
MAY 20, 2024
Researchers analyzed the efficacy of continuous glucose monitoring as the standard of care for diabetes management in an inpatient setting.
pharmaphorum
MAY 20, 2024
In this fireside chat webinar, experts break down the FDA's new PDURS framework for adding software to drug labels. Learn how it impacts pharma and what you need to know. Join us on Tuesday 9th July @ 07:00am PDT / 10:00am EDT / 15:00pm BST / 16:00pm CEST.
STAT
MAY 20, 2024
After his spinal cord injury in 2014, Sherown Campbell worked hard to regain as much bodily function as he could. Once a dedicated athlete, Campbell had to learn the new limits of his body. One of them, jarringly, was his body’s inability to sweat. So when Campbell started sweating on his stationary bike for the first time in seven years, it felt surreal.
Drug Topics
MAY 20, 2024
Findings from the FAMS-T1D study show that structured goal-setting and achievement significantly enhance self-efficacy and self-care in emerging adults.
Pharmacy Times
MAY 20, 2024
A review of the literature shows the sublingual vaccine holds promise for the treatment of this condition.
PharmaVoice
MAY 20, 2024
The “Nobel Prize-worthy invention” could be worth hundreds of billions commercially — and have a deep impact on drug R&D.
pharmaphorum
MAY 20, 2024
Shah Capital Management has withdrawn a proxy campaign against the re-election of director at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi. The top-three investor in Novavax – which has been steadily raising its stake in the company in recent weeks and now holds around 7.9% – said it welcomed the Sanofi deal but warned that “does not mean our engagement is at an end” and it still believes Novavax would benefit from a stockholder on its board of directors.
Fierce Pharma
MAY 20, 2024
A Delaware federal jury has ordered AstraZeneca to fork over $107.5 million to Pfizer for infringing two of the latter company's patents with its marketing of blockbuster oncology med Tagrisso. | Pfizer's Wyeth subsidiary and licensee Puma Biotechnology sued AstraZeneca in 2021 for alleged patent infringement related to AZ's marketing of cancer blockbuster Tagrisso.
pharmaphorum
MAY 20, 2024
Amgen and AstraZeneca have said their severe asthma therapy Tezspire could have a role to play in chronic obstructive pulmonary disease (COPD) – a key target indication for the drug – despite missing its primary objective in a clinical trial.
Fierce Pharma
MAY 20, 2024
The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space. | The biologics market for inflammatory bowel disease is continually getting more competitive, and now Johnson & Johnson’s Tremfya is the latest medicine angling to make a mark in the space.
STAT
MAY 20, 2024
Americans, especially Medicare beneficiaries, are getting more medical care these days. Demand from aging Baby Boomers is keeping people in doctor’s offices, and health care providers are continuing to build capacity post-Covid. Those trends — the same ones that tanked health insurance stocks a few weeks ago — made a strong mark on nonprofit health systems’ first quarter financial reports.
Fierce Pharma
MAY 20, 2024
Even as GSK defends itself against thousands of personal injury lawsuits relating to its sale of heartburn pill Zantac, a whistleblower lawsuit from the laboratory that first raised alarm bell | A newly unsealed complaint from the laboratory that first revealed Zantac's links to a carcinogenic impurity lays out a web of allegations about GSK's efforts to bring the drug to market in the 1980s and its attempts to hide the risks since then.
STAT
MAY 20, 2024
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow of money in medicine. Sign up to get it in your inbox every Monday. The nonprofits rake in a strong first quarter My colleague Tara Bannow and I are absolute suckers for reading hospital financial statements. A huge amount of those documents were released last week, and the numbers mirror what we’ve been seeing over the past several months : Not all hospitals are in dire str
The Checkup by Singlecare
MAY 20, 2024
Entresto is used in people to treat congestive heart failure ( CHF ). Currently, veterinarians do not use Entresto in dogs, but it may be more commonly used by veterinarians in the future. Two recent studies have shown that Entresto could be an effective treatment for canine heart failure. However, veterinarians already have several effective treatments for this type of heart disease.
STAT
MAY 20, 2024
In April, the U.S. Department of Health and Human Services, the world’s most powerful health care agency — responsible for overseeing the largest industry in the world’s largest economy — offered a pretend proposal for regulating health care’s massive carbon footprint of 550 million metric tons of carbon dioxide-equivalent (CO2e), or greenhouse gas (GHG) emissions.
European Pharmaceutical Review
MAY 20, 2024
A new $1.5 billion antibody drug conjugate (ADC) manufacturing facility in Singapore is set to increase global supply of AstraZeneca’s ADC portfolio. More about the ADC facility The planned greenfield facility will be the company’s first end-to-end ADC production site” The planned greenfield facility will be the company’s first end-to-end antibody drug conjugate production site.
The Checkup by Singlecare
MAY 20, 2024
People with attention deficit hyperactivity disorder ( ADHD ) may feel like they’re fighting a constant battle against distraction and impulsivity. Adderall can provide some much-needed help. Adderall is a central nervous system stimulant ( CNS ). It contains amphetamine and dextroamphetamine and works by increasing dopamine, serotonin, and norepinephrine.
pharmaphorum
MAY 20, 2024
Phase 2a data with drugs for idiopathic pulmonary fibrosis from Vicore and Endeavor raise hopes of disease-modifying therapy for the disease
Fierce Pharma
MAY 20, 2024
At the American Thoracic Society international conference in San Diego, one of the major themes is the advance of new therapies for chronic obstructive pulmonary disease (COPD). | At the American Thoracic Society international conference, one of the major themes is the advance of new therapies for COPD. On Monday, Sanofi and Regeneron had their answer to Amgen and AstraZeneca's presentation from the day before.
Expert insights. Personalized for you.
165 
Let's personalize your content